Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74

Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine that has been implicated in various inflammatory diseases. Chronic inflammation is a mainstay of liver fibrosis, a leading cause of morbidity worldwide, but the role of MIF in liver scarring has not yet been elucidated. Here we have uncovered an unexpected antifibrotic role for MIF. Mice genetically deleted in Mif (Mif−/−) showed strongly increased fibrosis in two models of chronic liver injury. Pronounced liver fibrosis in Mif−/− mice was associated with alterations in fibrosis-relevant genes, but not by a changed intrahepatic immune cell infiltration. Next, a direct impact of MIF on hepatic stellate cells (HSC) was assessed in vitro. Although MIF alone had only marginal effects on HSCs, it markedly inhibited PDGF-induced migration and proliferation of these cells. The inhibitory effects of MIF were mediated by CD74, which we detected as the most abundant known MIF receptor on HSCs. MIF promoted the phosphorylation of AMP-activated protein kinase (AMPK) in a CD74-dependent manner and, in turn, inhibition of AMPK reversed the inhibition of PDGF-induced HSC activation by MIF. The pivotal role of CD74 in MIF-mediated antifibrotic properties was further supported by augmented liver scarring of Cd74−/− mice. Moreover, mice treated with recombinant MIF displayed a reduced fibrogenic response in vivo. In conclusion, we describe a previously unexplored antifibrotic function of MIF that is mediated by the CD74/AMPK signaling pathway in HSCs. The results imply MIF and CD74 as targets for treatment of liver diseases.

[1]  C. Trautwein,et al.  Functional role of chemokines in liver disease models , 2010, Nature Reviews Gastroenterology &Hepatology.

[2]  C. Trautwein,et al.  Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. , 2010, The Journal of clinical investigation.

[3]  Jun Ren,et al.  Impaired Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Activation and Ischemic Recovery in the Senescent Heart , 2010, Circulation.

[4]  C. Trautwein,et al.  CXC chemokine ligand 4 (Cxcl4) is a platelet‐derived mediator of experimental liver fibrosis , 2010, Hepatology.

[5]  L. Leng,et al.  Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. , 2009, The Journal of clinical investigation.

[6]  A. Bielawska,et al.  AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells , 2009, Journal of Lipid Research.

[7]  J. H. van Bockel,et al.  MIF Deficiency Reduces Chronic Inflammation in White Adipose Tissue and Impairs the Development of Insulin Resistance, Glucose Intolerance, and Associated Atherosclerotic Disease , 2009, Circulation research.

[8]  F. Tacke,et al.  Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. , 2009, Gastroenterology.

[9]  Ritu Agarwal,et al.  Hepatic stellate cells express functional CXCR4: Role in stromal cell–derived factor‐1α–mediated stellate cell activation , 2009, Hepatology.

[10]  C. Trautwein,et al.  The Marburg I variant (G534E) of the factor VII–activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet‐derived growth factor BB , 2009, Hepatology.

[11]  K. Iczkowski,et al.  Cyclophosphamide-Induced Cystitis Increases Bladder CXCR4 Expression and CXCR4-Macrophage Migration Inhibitory Factor Association , 2008, PloS one.

[12]  J. Bernhagen,et al.  Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment , 2008, Proceedings of the National Academy of Sciences.

[13]  J. Bernhagen,et al.  Chemokine-like functions of MIF in atherosclerosis , 2008, Journal of Molecular Medicine.

[14]  J. Bernhagen,et al.  Macrophage Migration Inhibitory Factor in Cardiovascular Disease , 2008, Circulation.

[15]  D. Brenner,et al.  High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate–activated protein kinase , 2008, Hepatology.

[16]  F. Tacke,et al.  Protective Role of CXC Receptor 4/CXC Ligand 12 Unveils the Importance of Neutrophils in Atherosclerosis , 2008, Circulation research.

[17]  L. Leng,et al.  Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart , 2008, Nature.

[18]  S. Gelmini,et al.  Adenosine monophosphate–activated protein kinase modulates the activated phenotype of hepatic stellate cells , 2007, Hepatology.

[19]  S. Friedman.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. , 2008, Physiological reviews.

[20]  E. Morand,et al.  Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. , 2007, Inflammation & allergy drug targets.

[21]  Annette Lee,et al.  Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence , 2007, Genes and Immunity.

[22]  E. Dahl,et al.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity , 2007, Oncogene.

[23]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.

[24]  L. Zhuo,et al.  Expression and upregulation of cathepsin S and other early molecules required for antigen presentation in activated hepatic stellate cells upon IFN-gamma treatment. , 2007, Biochimica et biophysica acta.

[25]  K. Iczkowski,et al.  Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells1 , 2006, The Journal of Immunology.

[26]  A. Berrebi,et al.  Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. , 2006, Blood.

[27]  J. Bernhagen,et al.  MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis , 2006, Nature Reviews Drug Discovery.

[28]  M. Mori,et al.  Lack of macrophage migration inhibitory factor protects mice against concanavalin A‐induced liver injury , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[29]  Julia L. Gregory,et al.  Macrophage Migration Inhibitory Factor Induces Macrophage Recruitment via CC Chemokine Ligand 2 , 2006 .

[30]  D. Brenner,et al.  Erratum: Liver fibrosis (Journal of Clinical Investigation (2005) 115 (209-218) DOI:10.1172/JCI200524282) , 2005 .

[31]  Julia L. Gregory,et al.  Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. , 2004, Arthritis and rheumatism.

[32]  K. Meyer-Siegler,et al.  Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells , 2004, BMC Cancer.

[33]  V. Arroyo,et al.  Management of cirrhosis and ascites. , 2004, The New England journal of medicine.

[34]  T. Hosokawa,et al.  Immunohistochemical study of macrophage migration inhibitory factor in rat liver fibrosis induced by thioacetamide. , 2009, European journal of histochemistry : EJH.

[35]  S. Kihara,et al.  Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. , 2003, Gastroenterology.

[36]  D. Hardie.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0982 Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status , 2022 .

[37]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[38]  Yu Wang,et al.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.

[39]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[40]  P. Gregersen,et al.  A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis , 2002, Genes and Immunity.

[41]  P. Bioulac-Sage,et al.  [Mechanisms of hepatic fibrogenesis]. , 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[42]  R. Bucala,et al.  Protection from septic shock by neutralization of macrophage migration inhibitory factor , 2000, Nature Medicine.

[43]  H. El‐Serag,et al.  Rising Incidence of Hepatocellular Carcinoma in the United States , 1999, Infection Control & Hospital Epidemiology.

[44]  J. Wands,et al.  The increasing incidence of hepatocellular carcinoma. , 1999, The New England journal of medicine.

[45]  A. Odén,et al.  The rising incidence of hepatocellular carcinoma. , 1999, The New England journal of medicine.

[46]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[47]  K. Tracey,et al.  MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia , 1993, Nature.

[48]  A. Wendel,et al.  A T cell-dependent experimental liver injury in mice inducible by concanavalin A. , 1992, The Journal of clinical investigation.

[49]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.